A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1
|
作者：
Gill, Harpaul S. [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA
来源：
CANCER | 2019年 / 125卷 / 13期
关键词：
durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;
D O I：
10.1002/cncr.31996
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.
引用
收藏
页码：2148 / 2153
页数：6
相关论文
共 50 条
  • [1] Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer
    Ahn, Myung-Ju
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1205 - 1206
  • [2] Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
    Price, Katharine A. R.
    Azzoli, Christopher G.
    Gaspar, Laurie E.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 204 - 209
  • [3] Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?
    Wauters, Els
    Vansteenkiste, Johan
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 574 - 577
  • [4] Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
    Chalmers, Anna W.
    Patel, Shiven B.
    Akerley, Wallace
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1198 - 1200
  • [5] PROGNOSTIC FACTORS IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER
    Boku, S.
    Kasamatsu, Y.
    Kida, T.
    Kasamatsu, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [6] Optimal Treatment of Unresectable Stage III Non-Small Cell Lung Cancer
    Bradley, Jeffrey D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 853 - 855
  • [7] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [8] A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
    Bartolomeo, Valentina
    Cortiula, Francesco
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk
    Filippi, Andrea R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1455 - 1460
  • [9] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
  • [10] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Kazutaka Hosoya
    Daichi Fujimoto
    Hayato Kawachi
    Yuki Sato
    Mariko Kogo
    Kazuma Nagata
    Atsushi Nakagawa
    Ryo Tachikawa
    Shinya Hiraoka
    Masaki Kokubo
    Keisuke Tomii
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 275 - 280
12345